This study will include patients treated with ICS approved for asthma treatment in Denmark, including combination treatment with LABAs and/or LAMAs. The following drugs have been defined as IMPs (investigational medicinal product) in the study (approved by the Danish Medicines Agency): Budesonide (ATC: R03BA02), fluticasone propionate (ATC: R03BA05), mometasone furoate (ATC: R03BA07), fluticasone furoate (ATC: R03AK10), beclometasone dipropionate (ATC: R03BA01), and ciclesonide (ATC: R03BA08).
The study drugs will be additionally labelled (not covering the original label) with the following information: Name of sponsor/investigator, trial reference code “PERIOSTIN”, trial site, and participant ID (randomization number).
Free full text: Click here